September 11, 2026
Elevance surged 6% after signaling a Q3 beat. UnitedHealth fell 3% after reaffirming guidance
On Wednesday at the Wells Fargo 21st Annual Healthcare Conference, UnitedHealth Group CFO Wayne DeVeydt stood up and reaffirmed full-year 2026 adjusted earnings of $19.50 to $20.00 per share alongside about $24 billion in operating cash flow. The stock fell 3%. The next day, Elevance Health CFO Marc Kaye told the same conference that third-quarter adjusted earnings per share are tracking ahead of the company’s prior outlook. Elevance surged nearly 6%.
Pilots Use One. Smart Traders Should Too.
A pilot never takes off without running a checklist. Not because they don’t know how to fly – because they know that the moment something feels routine is the moment a step gets skipped.
Options trading punishes skipped steps faster than almost anything else. So, I put the 7 that matter most on one page.
It’s called the Smart Trade Options Checklist. Normally $29.97. Free today.
Run it before any options trade. Takes about 30 seconds. You’ll catch the bad ones before they cost you.
Same event. Same week. Opposite directions. The market was not confused. It was making a distinction that long-term investors should understand clearly.
What the Numbers Are Actually Saying
Elevance reaffirmed 2026 adjusted earnings guidance of at least $27.00 a share and said third-quarter results are running ahead of its second-quarter outlook. That last part is the key detail. A company telling you mid-quarter that it is outperforming its own internal targets is a different kind of signal than one confirming it will land inside a range it already set. Management also said 2026 should be the trough year for Medicaid margins, with improvement expected in 2027 as rates better match costs. Combined with the company’s view of at least 12% adjusted EPS growth in 2027 from the 2026 baseline, supported by multiple businesses rather than one segment alone, Elevance is not just defending a number. It is outlining a trajectory.
UnitedHealth’s story is more complicated. UnitedHealthcare now expects to end 2026 in the upper half of its 2% to 4% Medicare Advantage margin target range, CFO DeVeydt said Wednesday. That is genuine progress after a brutal stretch in that business. But the stock fell 3% after Bloomberg reported that UnitedHealth sold an interest in some of its Florida WellMed primary-care clinics, which sit inside Optum Health, the value-based care unit whose stumbles have driven UnitedHealth’s ongoing turnaround.
Inside the Nuclear Revival Reshaping Energy Markets
Governments worldwide are investing billions to revive a proven energy source. Supply chains are tightening, demand is rising, and select companies stand to benefit. The Nuclear’s Second Act report explains what’s happening next.
Why the WellMed Deal Unsettled Investors
TPG bought into some of UnitedHealth’s Florida WellMed clinics, with DeVeydt calling it a growth partnership rather than a capital raise. Maybe so. But investors remember that Optum was supposed to be the crown jewel. Selling a piece of it, even framed as partnership, raises a legitimate question about whether management is monetizing a problem rather than solving one.
Analyst consensus for UnitedHealth’s full-year 2026 adjusted EPS sits at $19.81, inside management’s range, and the 2027 consensus sits at $22.44. Those numbers are not unreasonable, but they depend on Optum Health executing a recovery that is still in progress. Management commentary around the conference also pointed to continued pressure in commercial cost trends, including costs tied to out-of-network disputes and elevated medical trends. The guidance range is intact. The credibility around it is still being earned.
Building Wealth Around This Divergence
The sector-level selloff many feared did not materialize. The health care sector ETF XLV dropped just 0.4% and peers Elevance and Humana held steady, confirming the selloff was UNH-specific, not a broader healthcare story. That matters for portfolio construction. Managed care as a group is not impaired. One name within it is still working through a turnaround, while others are demonstrating execution.
Inside the Nuclear Revival Reshaping Energy Markets
Governments worldwide are investing billions to revive a proven energy source. Supply chains are tightening, demand is rising, and select companies stand to benefit. The Nuclear’s Second Act report explains what’s happening next.
For investors who want health insurance exposure, the two-day conference essentially ran a live comparison. Elevance is showing improving cost trends across Medicare Advantage, Medicaid, and ACA. The picture is mixed, with favorable trends in Medicare Advantage and Medicaid, while employer group costs remain elevated. Elevance also highlighted stronger momentum at Carelon, its health services unit. Broad-based progress across multiple segments carries more weight than a single line improving.
UnitedHealth may yet deliver on its $19.50 to $20.00 range. The Medicare Advantage margin trend is moving in the right direction, and a full year of disciplined pricing should help. But a guidance reaffirmation is a floor, not a catalyst. The market already knew what that range was.
The Wealth Takeaway
Identical guidance headlines do not produce identical investments. When two companies stand at the same podium and say reassuring things, the one with the cleaner execution record and the upside surprise will always trade better. Owning a sector means choosing within it, not just owning it wholesale. This week made that distinction as visible as it gets.
